European Society for Medical Oncology

Type: Organization
Name: European Society for Medical Oncology
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Viralytics : Two CAVATAK poster presentations at ESMO

: The Company is pleased to share links to the two CAVATAK TM poster presentations from the European Society for Medical Oncology (ESMO) 2014 Congress, Madrid, Spain, September 26- 3 ... [Published 4 Traders - 3 hours ago]
First reported 5 hours ago - Updated 5 hours ago - 1 reports

EMD Serono Names Winners of GOI

EMD Serono reported the winners of the first Grant for Oncology Innovation (GOI), who will receive grants totaling $1.3 million. According to a release from the company, the 2014 winners were formally released at an awards ceremony coinciding with the ... [Published Individual.com - 5 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

New cancer therapy comes of age, cost a toxic side effect

MADRID: A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects -- but their high cost is a growing concern.Drugs that help the body´s own immune cells fight tumours are expected to be used in multi-drug cocktails, ... [Published The News International - 8 hours ago]
First reported 14 hours ago - Updated 12 hours ago - 1 reports

ESMO 2014: New Regimen for BRAF-mutated Melanoma

For patients with advanced melanoma that is BRAF -mutation positive, the combination of a BRAF and MEK inhibitor works better than a BRAF inhibitor alone. The data come from 2 phase 3 trials presented here at the presidential session of the European Society ... [Published American Journal of Managed Care - 14 hours ago]
First reported 16 hours ago - Updated 15 hours ago - 1 reports

Novel Rose Bengal Formulation Obliterates Lesions in Patients with Deadliest of Melanomas

Data Presented at the European Society for Medical Oncology Congress in Spain Shows New Approach offers Overall Response Rate of 71% Contact InformationAvailable for logged-in reporters onlyCitationsEuropean Society for Medical OncologyNewswise — A formulation ... [Published Newswise - 16 hours ago]
First reported 20 hours ago - Updated 16 hours ago - 1 reports

Successful clinical trial for new melanoma drug combo

A recent clinical trial has shown positive results for a combination therapy drug used to treat people with advanced melanoma .Following a phase III clinical trial, Roche confirmed the benefits of combining two drugs, cobimetinib and Zelboraf, togeth ... [Published Pharma Field - 20 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Cancer Immunotherapy Drugs Show Efficacy In Early, Mid-Stage Trials

The European Society for Medical Oncology Conference, which kicked off past Friday, has shed light on the cancer immunotherapy pipeline for many industry players. Here's a roundup of the developmentsPage 1 of 2Click Ticker to See live coverageThe immunotherapy ... [Published Bidness Etc - 18 hours ago]
First reported Sep 29 2014 - Updated Sep 30 2014 - 2 reports

Merck‘s Keytruda Effective In Fighting Stomach Cancer

Merck announced at the European Society for Medical Oncology (ESMO) conference that Keytruda is effective in reducing the size of tumors in patients suffering from stomach cancer, and is being tested for treating five types of tumorsPage 1 of 2Click Ticker ... [Published Bidness Etc - Sep 29 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 3 reports

Drugs combination could help skin cancer patients extend life

Data presented at the European Society for Medical Oncology (ESMO) Congress in Madrid showed that treating patients suffering from advanced melanoma with both cobimetinib and vemurafenib could prevent their disease from progressing for up to 9.9 months. ... [Published NewsRT.co.uk - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 30 2014 - 3 reports

Wider use of breast cancer drug urged after ‘unprecedented’ benefits

A breast cancer drug has shown "unprecedented" benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease.Patients with a type of breast cancer known as HER2 positive — which ... [Published Irish Examiner - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 2 reports

Array's Melanoma Drug Promising in Phase 2

Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.Invented by Array BioPharma Inc. and licensed to Novartis ... [Published Drug Discovery and Development - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 2 reports

The Oncotype DX® Test and Precision Oncology: New Data Presented at ESMO Further Demonstrate Genomic Health’s Successful Approach to Understanding Tumour Biology

GENEVA--(BUSINESS WIRE)--In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress - ‘Precision Medicine in Cancer Care’ - Genomic Health presented results from multiple studies across different cancer types demonstrating ... [Published Business Wire Science: Science News - Sep 29 2014]

Quotes

...options for patients with squamous cell carcinoma," said Suresh S Ramalingam, M D , director, Division of Medical Oncology, Emory University. "These data demonstrate activity for veliparib in non-small cell lung cancer patients with squamous histology. The combination of veliparib with chemotherapy merits further evaluation in squamous cell lung cancer."
...pancreatic neuroendocrine tumors," said James Yao*, MD, lead investigator, The University of Texas MD Anderson Cancer Center, Houston, Texas. "The results affirm the importance of targeting key pathways involved in tumor growth, such as the mTOR pathway in advanced pNET."
...a personalized approach to patient care," said Belen Garijo, President and CEO of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. "We hope that this first Grant for Oncology Innovation will help enable further pioneering research into the personalized treatment of cancer that may ultimately lead to improved clinical outcomes for patients."
"Financial toxicity, or more generally the financial burden of disease, is a side effect just as potent as fatigue or nausea in patients" consultancy IMS Health said in a report last week, noting the average price of cancer drugs had almost doubled in the past decade to $10,000 a month...

More Content

All (269) | News (236) | Reports (0) | Blogs (26) | Audio/Video (0) | Fact Sheets (0) | Press Releases (7)
sort by: Date | Relevance
ESMO 2014: Eisai’s lenvatinib could revolutioni... [Published Pharma Letter - 2 hours ago]
SIR-Spheres(R) y-90 Resin Microspheres Recommen... [Published Newswit.com - 2 hours ago]
Viralytics : Two CAVATAK poster presentations a... [Published 4 Traders - 3 hours ago]
AbbVie Posts Results from Phase 2 Study of Inve... [Published Individual.com - 5 hours ago]
Novartis Reports Results on Overall Survival fr... [Published Individual.com - 5 hours ago]
EMD Serono Names Winners of GOI [Published Individual.com - 5 hours ago]
New cancer therapy comes of age, cost a toxic s... [Published The News International - 8 hours ago]
ESMO 2014: New Regimen for BRAF-mutated Melanoma [Published American Journal of Managed Care - 14 hours ago]
Pertuzumab ups survival in HER2-positive metast... [Published Drugtopics.com - 14 hours ago]
CLEOPATRA: Pertuzumab Ups Survival by 16 Months... [Published Cancernetwork.com - 15 hours ago]
Novel Rose Bengal Formulation Obliterates Lesio... [Published Newswise - 16 hours ago]
GE, GSK partner to develop genetic oncology tes... [Published FierceMedicalDevices - 17 hours ago]
ESMO 2014: Takeda and Seattle Genetics' Adcetri... [Published Pharma Letter - 17 hours ago]
Cancer Immunotherapy Drugs Show Efficacy In Ear... [Published Bidness Etc - 18 hours ago]
For HER2-Positive Breast Cancer, Trastuzumab Mo... [Published Chemotherapy Advisor - 18 hours ago]
Successful clinical trial for new melanoma drug... [Published Pharma Field - 20 hours ago]
News Standard in Melanoma: Combo of BRAF and ME... [Published Diabetes Care - 20 hours ago]
Herceptin Best for Certain Breast Cancer Patien... [Published Bio-Medicine - 21 hours ago]
Melanoma drug combo improves patient survival r... [Published Medical News Today - 21 hours ago]
Roche reports positive data from new melanoma t... [Published Zenopa - 21 hours ago]
Zytiga® (abiraterone acetate) survival data in ... [Published Medical News Today - Sep 30 2014]
Janssen, AZ and Roche at ESMO [Published PMLive - Sep 30 2014]
ESMO 2014: GSK reports 45% survival rate in Taf... [Published Pharma Letter - Sep 30 2014]
Skin cancer sufferers lives 'prolonged' with dr... [Published Stv.tv - Sep 30 2014]
Cancer Drug From Roche Shows Promise For Increa... [Published Zolmax News - Sep 30 2014]
Drugs combination could help skin cancer patien... [Published NewsRT.co.uk - Sep 30 2014]
Melanoma treatment’s landmark trial [Published Herald Sun - Sep 30 2014]
Needed: Expanded RAS Mutation Analysis for Pred... [Published Oncology Times - Sep 30 2014]
Medidata Appoints Mike Capone COO; PV-10 Data a... [Published BioMedReports - Sep 30 2014]
Genentech gets good news on breast cancer drug,... [Published San Francisco Chronicle - Sep 30 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The Oncotype DX® Test and Precision Oncology: N... [Published EON Science - Sep 29 2014]
GENEVA--(EON: Enhanced Online News)--In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress - ‘Precision Medicine in Cancer Care’ - Genomic Health presented results from multiple studies across different cancer ...
The Oncotype DX® Test and Precision Oncology: N... [Published Business Wire Science: Science News - Sep 29 2014]
GENEVA--(BUSINESS WIRE)--In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress - ‘Precision Medicine in Cancer Care’ - Genomic Health presented results from multiple studies across different cancer types demonstrating ...
The Oncotype DX® Test and Precision Oncology: N... [Published Business Wire Health News - Sep 29 2014]
GENEVA--(BUSINESS WIRE)--In line with this year’s theme for the annual European Society for Medical Oncology (ESMO) Congress - ‘Precision Medicine in Cancer Care’ - Genomic Health presented results from multiple studies across different cancer types demonstrating ...
Phase 2 Trial Of Binimetinib In NRAS Melanoma S... [Published PR Newswire: Health - Sep 29 2014]
BOULDER, Colo., Sept. 29, 2014 /PRNewswire/ -- Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented today at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.  ...
SIR-Spheres® y-90 Resin Microspheres Recommende... [Published PR Newswire: Health - Sep 29 2014]
BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Bionomics Presents BNC105 Phase II Renal Cancer... [Published GlobeNewswire: Acquisitions News - Sep 29 2014]
TRACON Pharmaceuticals Announces Results From C... [Published GlobeNewswire: Acquisitions News - Sep 24 2014]
Data from Study of Champions Oncology TumorGraf... [Published Financial Services - Sep 24 2014]
Endocyte Announces Late-Breaking Abstract Prese... [Published GlobeNewswire: Advertising News - Sep 22 2014]
Merrimack Pharmaceuticals to Present Clinical a... [Published GlobeNewswire: Advertising News - Sep 19 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.